# Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

> **NCT00260039** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 680 (actual)

## Conditions studied

- HPV
- Cervical Cancer
- Premalignancy Anogenital Warts

## Interventions

- **BIOLOGICAL:** Comparator: Gardasil
- **BIOLOGICAL:** Comparator: octavalent HPV Vaccine - dose formulation 1
- **BIOLOGICAL:** Comparator: octavalent HPV Vaccine - dose formulation 2
- **BIOLOGICAL:** Comparator: octavalent HPV Vaccine - dose formulation 3

## Key facts

- **NCT ID:** NCT00260039
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 680 (ACTUAL)
- **Last updated:** 2015-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00260039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00260039, "Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT00260039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*